MarkStephenGelderMD

Obstetrics & Gynecology • Phoenixville, PA

Gynecologic Oncology, Urogynecology & Pelvic Reconstructive Surgery

SVP & Chief Medical Officer Heron Therapeutics

Join to view full profile

Dr. Gelder is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Gelder's full profile

Already have an account?

Office
200 Rivercrest Drive
Phoenixville, PA 19460
Is this information wrong?

Education & Training

University of Virginia School of MedicineClass of 1982

Clinical Trials

A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC Start of enrollment: 2014 Mar 01
Completed
Phase 3

Publications & Presentations

PubMed

25 citations
Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron.
Thomas Ottoboni, Mark S Gelder, Erin O’Boyle> ;Journal of Experimental Pharmacology. 2014 Dec 9

Press Mentions

Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark GelderApril 6th, 2023
Onconova Therapeutics Provides an Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS Non-Small Cell Lung CancerJune 28th, 2021
Two Months After Inking a SPAC Deal, Renovacor Taps New CMO; CureVac Reels in a New Development Chief from Merck KGaAJune 4th, 2021
Join now to see all